Compare XRX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | STRO |
|---|---|---|
| Founded | 1906 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 381.1M |
| IPO Year | 2019 | N/A |
| Metric | XRX | STRO |
|---|---|---|
| Price | $3.26 | $25.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $2.50 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 3.7M | 238.8K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ 23.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | N/A |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $0.72 |
| 52 Week High | $4.42 | $43.85 |
| Indicator | XRX | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 42.84 |
| Support Level | $2.40 | $23.53 |
| Resistance Level | $3.74 | $27.96 |
| Average True Range (ATR) | 0.25 | 1.59 |
| MACD | 0.06 | 0.28 |
| Stochastic Oscillator | 55.91 | 52.48 |
Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.